Reporting side effects of medicines
EMA launches survey to assess whether patients and doctors are aware of the arrangements for reporting of side effects
The European Medicines Agency (EMA) has launched a survey to better understand patients’ and healthcare professionals’ awareness of reporting adverse drug reactions, including for medicines under ‘additional monitoring’.
Medicines under additional monitoring are monitored particularly closely by regulatory authorities. They are easily identified by a black inverted triangle displayed in their package leaflet and in the information for healthcare professionals, called the ‘summary of product characteristics’ (SmPC). Healthcare professionals and patients are encouraged to report any suspected adverse reactions.
Regulatory authorities continuously look at reports of side effects alongside all the information they already have to make sure that the benefits of medicines remain greater than their risks and to take any necessary action.
The survey’s main aim is to evaluate the awareness, attitudes and reporting behaviours of patients and healthcare professionals to report side effects. The questionnaire is translated into all official European Union languages and takes no more than 10 minutes to complete. It will be open for responses until 9 October 2017. The results of the survey will be analysed by EMA and the European Commission and the conclusions will be published in 2018.
- Medicines under additional monitoring
- Partners and networks: healthcare professionals
- Partners and networks: patients and consumers
- Healthcare professionals: information for you
- Patients and carers: information for you
Latest News from
A framework for the free flow of non-personal data in the EU – Q&As20/09/2017 12:25:00
With the Regulation on the free flow of non-personal data, the EC proposes a new principle that abolishes data localisation requirements while ensuring access rights to competent authorities for regulatory control.
State aid: EC approves alternative to divestment commitment for Royal Bank of Scotland19/09/2017 14:10:00
The EC has approved under EU State aid rules the alternative package proposed by the UK authorities to replace the commitment for Royal Bank of Scotland (RBS) to divest Williams & Glyn. The alternative package will increase competition in the UK SME banking market.
EC welcomes stakeholders' views on the future of EU finances19/09/2017 12:49:00
As part of the process started with the publication of the Reflection Paper on the Future of EU finances, the EC is organising on 25 September 2017 a conference on the challenges ahead of the EU budget and the ways to address them.
Juncker: ‘I don't intend to force countries to join the euro if they are not willing or not able to do so'18/09/2017 15:20:00
Jean-Claude Juncker, the President of the EC,has defended his proposal to expand the eurozone. All EU Member States should have the possibility to introduce the euro, but no one would be forced to do so, Juncker said on Thursday.
EMA concludes review of human factor VIII medicines authorised in EU.18/09/2017 13:20:00
The European Medicines Agency (EMA) has concluded that there is no clear & consistent evidence of a difference in the incidence of inhibitor development between the two classes of factor VIII medicines: those derived from plasma and those made by recombinant DNA technology.